Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy-Reference-Cited by-同舟云学术

Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy

Published:2021-09 Issue:26 Volume:17 Page:3485-3497
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

McBride Ali¹²³⁴^ORCID,Alrawashdh Neda²⁵^ORCID,Bartels Trace¹,Moore Logan¹,Persky Daniel¹,Abraham Ivo²³⁴⁵⁶^ORCID

Affiliation:

1. Banner University Medical Center, Tucson, AZ 85719, USA

2. Center for Health Outcomes & PharmacoEconomic Research, University of Arizona, Tucson, AZ 85721, USA

3. Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA

4. University of Arizona Cancer Center, Tucson, AZ 85719, USA

5. Clinical Translational Sciences, College of Medicine, University of Arizona, Tucson, AZ 85724, USA

6. Matrix45, Tucson, AZ 85743, USA

Abstract

Aim: To compare the incidence of febrile neutropenia and related outcomes of prophylactic same-day versus next-day pegfilgrastim/pegfilgrastim-cbqv in patients with lymphoma receiving cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone (CHOP)-like chemotherapy. Methods: Retrospective, real-world, single-institution study. Results: 93 patients received 460 cycles of CHOP-like chemotherapy. The incidence of febrile neutropenia and grade 3/4 chemotherapy-induced neutropenia was 5 and 16.5%, respectively. In 401 cycles pegfilgrastim was administered same-day versus 12 cycles next-day. Febrile neutropenia occurred in 17 cycles versus 0 cycles (p = 1.00) and grade 3/4 chemotherapy-induced neutropenia in 65 cycles (16.2%) versus 1 cycle (16.7%; p = 1.00) with same-day versus next-day pegfilgrastim administration, respectively. Conclusion: Pegfilgrastim may be safely administered on the same day as chemotherapy in patients with lymphoma receiving CHOP-like chemotherapy.

Funder

Coherus BioSciences

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0532

Reference37 articles.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic Growth Factors. Version 2.2021. (2021).

2. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

3. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012

4. US Bureau of Labor Statistics. CPI inflation calculator. https://www.bls.gov/data/inflation_calculator.htm

5. Federal Reserve Bank of St. Louis. Consumer price index for all urban consumers: medical care in U.S. city average (CPIMEDSL). https://fred.stlouisfed.org/series/CPIMEDSL

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining primary refractory large B-cell lymphoma;Blood Advances;2024-06-26

2. On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status;Cancer Treatment and Research Communications;2024

3. Two decades of pegfilgrastim: what have we learned? Where do we go from here?;Current Medical Research and Opinion;2023-04-08

4. Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis;Journal of Oncology Pharmacy Practice;2022-12-29

5. Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy;Future Oncology;2022-07